{"organizations": [], "uuid": "59669556d08067b86614e4a6587ffebdf2507b73", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 9, "shares": 9, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-7173/social", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/bristol-myers-has-farther-to-fall-1523893124", "country": "US", "domain_rank": 387, "title": "Bristol-Myers has Farther to Fall", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.992, "site_type": "news", "published": "2018-04-16T19:38:00.000+03:00", "replies_count": 0, "uuid": "59669556d08067b86614e4a6587ffebdf2507b73"}, "author": "Charley Grant", "url": "https://www.wsj.com/articles/bristol-myers-has-farther-to-fall-1523893124", "ord_in_thread": 0, "title": "Bristol-Myers has Farther to Fall", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fall bristol-myers squibb", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Bristol-Myers Squibb shareholders have a valuation problem.\nShares dove 8% Monday after the company unveiled mixed clinical data in a carefully watched trial for patients with lung cancer. Bristol-Myers announced its combination of immunotherapy drugs significantly reduced the risk of disease progression or death in a small subset of patients, but results were weaker in other arms of the trial.\n\nMixed...  ", "external_links": [], "published": "2018-04-16T19:38:00.000+03:00", "crawled": "2018-04-17T02:45:51.002+03:00", "highlightTitle": ""}